Eleven Biotherapeutics (Cambridge, MA) a preclinical-stage biopharmaceutical company focused on protein therapeutics for the treatment of inflammation and coagulation disorders, closed a $35M Series A financing. Participants include Flagship Ventures and Third Rock Ventures.
_________________________________________________________________________
NOTE: New OnBioVC Friday feature coming, well…this Friday!

Merus (Netherlands) a preclinical-stage biopharmaceutical focused on antibody product candidates against targets in oncology, inflammation and infectious disease, closed a $30.7M Series B financing. Participants include Novartis Option Fund, Pfizer, Bay City Capital, Life Sciences Partners and Aglaia Biomedical Ventures.

CalciMedica (La Jolla, CA) a preclinical-stage small molecule company focused on autoimmune and inflammatory via the inhibition of calcium release-activated calcium (CRAC) channels, closed a $5M Series C financing, bringing the total round up to $9M. Participants include Biogen Idec, Sanderling Ventures and SR One.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Probiodrug (Germany) a clinical-stage small molecule biopharmaceutical company focused upon Alzheimer’s and inflammation diseases, closed a $54M Series B financing. Participants include BB Biotech, Edmond de Rothschild Investment Partners, Life Science Partners, Biogen Idec New Ventures, HBM Bioventures and TVM Capital.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Oxagen (United Kingdom) a clinical-stage biopharmaceutical company focused on asthma and allergic rhinitis based drug company focused on inflammation, closed a $25.M Series C financing. Participants include MPM Capital, SV Life Sciences, Advent Ventures, Bessemer Venture Partners, Omega Ventures, Abingworth, International Bio Trust, Red Abbey Venture Partners and Wellcome Trust.

Note: 2009 Year-in-Review Trend Analysis Coming [...]

Xigen (Switzerland) a clinical-stage biopharma company focused on Jun Kinase inhibitor for stroke, inflammation and hearing loss, closed a $20M Series B financing. Participants have included Tilocor Life Sciences, VI Partners and DEFI Gestion.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

GlycoMimetics (Gaithersburg, MD) a clinical-stage small molecule glycobiology company focused on cancer, inflammation and infectious disease, closed a $38M Series C financing. Participants include Genzyme Ventures, New Enterprise Associates, Novartis Venture Fund, Anthem Capital Management and Alliance Technology Ventures.
A more detailed company profile recently appeared on Life Science Deal Flow [HERE].

Virdante Pharmaceuticals (Cambridge, MA) a development-stage biopharmaceutical company focused on increasing potency of plasma-derived intravenous immune globulin for the treatment of inflammation and autoimmune disease, closed a $30M Series A financing. Participants include Thomas, McNerney & Partners, Osage Partners, Clarus Ventures, Venrock, MedImmune Ventures and Biogen Idec New Ventures.

PharmAbcine (South Korea) a development-stage biopharma company focused on the development of monoclonal antibodies for cancer and inflammatory disease, closed a $6M Series A financing. Participants include OrbiMed, Novartis Venture Fund, Green Cross, Tong Yang Venture Capital and Saehan Venture Fund.

Acetylon Pharmaceuticals (Cambridge, MA) a development-stage small molecule company focused on Histone deacetylase inhibitors for oncology and inflammation indications, closed a $7.2M Series A financing. Participants may include Kraft Group Private Equity.